Glenview is the largest shareholder of the for-profit, publicly traded Health Management, owning roughly 14.6 percent of all Health Management shares. This week, Glenview executives filed documents in which it “urged” Health Management to throw out or amend its recently ratified “poison pill,” which is a plan that prevents the hostile takeover of a publicly traded company by a large shareholder.
In May, Health Management approved the poison pill, which included a 15 percent trigger, meaning if any shareholder acquired an ownership stake of 15 percent or higher, other shareholders would be protected and could potentially buy new shares for a steep discount.
Health Management’s terse news release said it is working with Morgan Stanley and Weil, Gotshal & Manges to consider “strategic alternatives,” though clarification of those alternatives was not provided. For the past couple weeks, many financial analysts have said the string of events could lead to another for-profit hospital company or a private equity firm taking over Health Management.
Health Management also announced it has begun a formal search to replace outgoing CEO Gary Newsome, who is retiring effective July 31.
More Articles on Health Management Associates:
Analysts Say HMA Financially Better Merger Partner for Bert Fish
Glenview Capital to HMA: Remove or Amend “Poison Pill”
HMA Signs Letter of Intent to Lease Munroe Regional Medical Center
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
